Balsalazide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 527041

CAS#: 80573-04-2

Description: Balsalazide is an anti-inflammatory agent for treatment of Inflammatory Bowel Disease.


Price and Availability

Size
Price

Size
Price

Size
Price

Balsalazide is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 527041
Name: Balsalazide
CAS#: 80573-04-2
Chemical Formula: C17H15N3O6
Exact Mass: 357.0961
Molecular Weight: 357.322
Elemental Analysis: C, 57.14; H, 4.23; N, 11.76; O, 26.86


Synonym: Balsalazide

IUPAC/Chemical Name: (E)-5-[[[-4-(2-Carboxyethyl)aminocarbonyl]phenyl]azo]-2-hydroxybenzoic acid

InChi Key: IPOKCKJONYRRHP-FMQUCBEESA-N

InChi Code: InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)/b20-19+

SMILES Code: O=C(O)C1=CC(/N=N/C2=CC=C(C(NCCC(O)=O)=O)C=C2)=CC=C1O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Kim SL, Kim SH, Park YR, Liu YC, Kim EM, Jeong HJ, Kim YN, Seo SY, Kim IH, Lee SO, Lee ST, Kim SW. Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-κB Activation. Mol Cancer Res. 2017 Feb;15(2):141-151. doi: 10.1158/1541-7786.MCR-16-0101. Epub 2016 Nov 14. PubMed PMID: 28108625.

2: Hofmann D, Gans E, Krüll J, Heinrich MR. Sustainable Synthesis of Balsalazide and Sulfasalazine Based on Diazotization with Low Concentrations of Nitrogen Dioxide in Air. Chemistry. 2017 Mar 23;23(17):4042-4045. doi: 10.1002/chem.201605359. Epub 2017 Jan 25. PubMed PMID: 28054726.

3: Wang Y, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016 May 9;(5):CD000544. doi: 10.1002/14651858.CD000544.pub4. Review. PubMed PMID: 27158764.

4: Do EJ, Hwang SW, Kim SY, Ryu YM, Cho EA, Chung EJ, Park S, Lee HJ, Byeon JS, Ye BD, Yang DH, Park SH, Yang SK, Kim JH, Myung SJ. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. J Gastroenterol Hepatol. 2016 Aug;31(8):1453-61. doi: 10.1111/jgh.13280. PubMed PMID: 26711554.

5: Kim HY, Kim SL, Park YR, Liu YC, Seo SY, Kim SH, Kim IH, Lee SO, Lee ST, Kim SW. Balsalazide Potentiates Parthenolide-Mediated Inhibition of Nuclear Factor-κB Signaling in HCT116 Human Colorectal Cancer Cells. Intest Res. 2015 Jul;13(3):233-41. doi: 10.5217/ir.2015.13.3.233. Epub 2015 Jun 9. PubMed PMID: 26130998; PubMed Central PMCID: PMC4479738.

6: Sousa T, Yadav V, Zann V, Borde A, Abrahamsson B, Basit AW. On the colonic bacterial metabolism of azo-bonded prodrugsof 5-aminosalicylic acid. J Pharm Sci. 2014 Oct;103(10):3171-5. doi: 10.1002/jps.24103. Epub 2014 Aug 4. PubMed PMID: 25091594.

7: Dhaneshwar SS. Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease. World J Gastroenterol. 2014 Apr 7;20(13):3564-71. doi: 10.3748/wjg.v20.i13.3564. Review. PubMed PMID: 24707139; PubMed Central PMCID: PMC3974523.

8: Coman RM, Glover SC, Gjymishka A. Febrile pleuropericarditis, a potentially life-threatening adverse event of balsalazide--case report and literature review of the side effects of 5-aminosalicylates. Expert Rev Clin Immunol. 2014 May;10(5):667-75. doi: 10.1586/1744666X.2014.902313. Epub 2014 Apr 1. Review. PubMed PMID: 24689504.

9: Russo L, Schneider G, Gardiner MH, Lanes S, Streck P, Rosen S. Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine. Eur J Clin Pharmacol. 2014 Jun;70(6):709-17. doi: 10.1007/s00228-014-1660-7. Epub 2014 Mar 11. PubMed PMID: 24609467; PubMed Central PMCID: PMC4025187.

10: Sim E, Abuhammad A, Ryan A. Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery. Br J Pharmacol. 2014 Jun;171(11):2705-25. doi: 10.1111/bph.12598. Review. PubMed PMID: 24467436; PubMed Central PMCID: PMC4158862.

11: Sun H, Lee JJ, Papadopoulos EJ, Lee CS, Nelson RM, Sachs HC, Rodriguez WJ, Mulberg AE. Alternate endpoints and clinical outcome assessments in pediatric ulcerative colitis registration trials. J Pediatr Gastroenterol Nutr. 2014 Jan;58(1):12-7. doi: 10.1097/MPG.0000000000000186. PubMed PMID: 24121142.

12: Huang HL, Lu PL, Lin CY, Chen YH, Kuo CH, Lin WR. Klebsiella pneumoniae bacteremia and renosplenic abscesses without intestinal symptoms as the initial manifestations of non-steroidal anti-inflammatory drug-induced colitis: a rare case report. BMC Gastroenterol. 2013 Sep 22;13:139. doi: 10.1186/1471-230X-13-139. PubMed PMID: 24053429; PubMed Central PMCID: PMC3849536.

13: Sonu I, Wong R, Rothenberg ME. 5-ASA induced recurrent myopericarditis and cardiac tamponade in a patient with ulcerative colitis. Dig Dis Sci. 2013 Aug;58(8):2148-50. doi: 10.1007/s10620-013-2566-4. Epub 2013 Jan 30. PubMed PMID: 23361575.

14: Kang SM, Jang YR, Yoon HH, Kim S, Kim EY, Ha SY, Park JW. A Case of Balsalazide-Induced Limited Form of Granulomatosis with Polyangiitis with Bronchiolitis Obliterans Organizing Pneumonia-like Variant in Ulcerative Colitis. Tuberc Respir Dis (Seoul). 2012 Mar;72(3):323-7. doi: 10.4046/trd.2012.72.3.323. Epub 2012 Mar 31. PubMed PMID: 23227073; PubMed Central PMCID: PMC3510283.

15: Yen L, Wu J, Hodgkins PL, Cohen RD, Nichol MB. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis. J Manag Care Pharm. 2012 Nov-Dec;18(9):701-12. PubMed PMID: 23206213.

16: Love BL, Miller AD. Extended-release mesalamine granules for ulcerative colitis. Ann Pharmacother. 2012 Nov;46(11):1529-36. doi: 10.1345/aph.1R171. Epub 2012 Oct 31. Review. PubMed PMID: 23115226.

17: Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012 Oct 17;10:CD000544. doi: 10.1002/14651858.CD000544.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;(5):CD000544. PubMed PMID: 23076890.

18: Unlü C, Daniels L, Vrouenraets BC, Boermeester MA. Systematic review of medical therapy to prevent recurrent diverticulitis. Int J Colorectal Dis. 2012 Sep;27(9):1131-6. doi: 10.1007/s00384-012-1486-7. Epub 2012 May 11. Review. PubMed PMID: 22576905.

19: Kane SV, Sumner M, Solomon D, Jenkins M. Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database. Dig Dis Sci. 2011 Dec;56(12):3463-70. doi: 10.1007/s10620-011-1877-6. Epub 2011 Aug 31. PubMed PMID: 21879279.

20: Ryan A, Wang CJ, Laurieri N, Westwood I, Sim E. Reaction mechanism of azoreductases suggests convergent evolution with quinone oxidoreductases. Protein Cell. 2010 Aug;1(8):780-90. doi: 10.1007/s13238-010-0090-2. Epub 2010 Aug 28. PubMed PMID: 21203919; PubMed Central PMCID: PMC4875192.